Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Nanda Nisha

2. Date of Event Requiring Statement (MM/DD/YYYY) 1/2/2019

3. Issuer Name and Ticker or Trading Symbol

Loxo Oncology, Inc. [LOXO]

(Last) (First) (Middle)

C/O LOXO ONCOLOGY, INC., 281 TRESSER BOULEVARD, 9TH FLOOR

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below)
Chief Development Officer /

(Street)

STAMFORD, CT 06901

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	18896	D

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee Stock Option (Right to Buy)	⁽¹⁾	3/3/2024	Common Stock	16983	$1.184	D
Employee Stock Option (Right to Buy)	⁽¹⁾	3/3/2024	Common Stock	14828	$1.184	D
Employee Stock Option (Right to Buy)	⁽¹⁾	6/18/2024	Common Stock	4557	$3.648	D
Employee Stock Option (Right to Buy)	⁽¹⁾	12/18/2024	Common Stock	10861	$13.67	D
Employee Stock Option (Right to Buy)	⁽²⁾	12/15/2025	Common Stock	9228	$31.69	D
Employee Stock Option (Right to Buy)	⁽³⁾	9/14/2026	Common Stock	14870	$27.00	D
Employee Stock Option (Right to Buy)	⁽⁴⁾	12/5/2026	Common Stock	18375	$26.27	D
Employee Stock Option (Right to Buy)	⁽⁵⁾	3/14/2027	Common Stock	12000	$43.56	D
Employee Stock Option (Right to Buy)	⁽⁶⁾	1/3/2028	Common Stock	75000	$84.88	D

Explanation of Responses:
(1)	The stock option is fully vested and exercisable.
(2)	The stock option vests and becomes exercisable as to 1/48th of the total number of shares on January 16, 2016, then an additional 1/48th vests on each monthly anniversary thereafter, until such time as the option is 100% vested, subject to the reporting person's continued service through each vesting date.
(3)	The stock option vests and becomes exercisable as to 1/48th of the total number of shares on October 15, 2016, then an additional 1/48th vests on each monthly anniversary thereafter, until such time as the option is 100% vested, subject to the reporting person's continued service through each vesting date.
(4)	The stock option vests and becomes exercisable as to 1/48th of the total number of shares on January 6, 2017, then an additional 1/48th vests on each monthly anniversary thereafter, until such time as the option is 100% vested, subject to the reporting person's continued service through each vesting date.
(5)	The stock option vests and becomes exercisable as to 1/48th of the total number of shares on April 15, 2017, then an additional 1/48th vests on each monthly anniversary thereafter, until such time as the option is 100% vested, subject to the reporting person's continued service through each vesting date.
(6)	The stock option vests and becomes exercisable as to 1/24th of the total number of shares on March 4, 2018, then an additional 1/48th vests on each monthly anniversary thereafter, until such time as the option is 100% vested, subject to the reporting person's continued service through each vesting date.

Remarks:
Exhibit List - Exhibit 24.1 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Nanda Nisha C/O LOXO ONCOLOGY, INC. 281 TRESSER BOULEVARD, 9TH FLOOR STAMFORD, CT 06901			Chief Development Officer

Signatures
/s/Jennifer Burstein, by power of attorney		1/2/2019
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.